. 2008 Nov 17;30(1):71–77. doi: 10.1093/carcin/bgn258

Table III.

Haplotype analysis of COMT, CYP1B1, CYP17A1, CYP19A1, HSD17B1 and SHBG and gastric cancer risk

Gene	LD block #	Haplotype^a	% of controls	% of cases	Global P^b	OR-1^c	95% CI	OR-2^d	95% CI
COMT	Block #1	ACTT	35.8	29.3	0.22	1.00	Reference	1.00	Reference
		AGCC	24.0	23.1		1.16	0.87–1.56	1.11	0.82–1.51
		GGTT	9.6	9.7		1.17	0.76–1.79	1.16	0.75–1.79
		ACTC	9.0	9.4		1.25	0.80–1.96	1.25	0.79–1.98
		ACCC	7.8	9.9		1.48	0.96–2.30	1.45	0.92–2.29
	Block #2	GATA	63.2	55.7	0.033	1.00	Reference	1.00	Reference
		AACA	14.9	17.5		1.33	0.99–1.80	1.36	1.00–1.85
		GGCG	9.6	8.2		0.94	0.63–1.42	0.97	0.64–1.47
		GATG	5.2	8.9		1.43	1.02–2.01	1.50	1.06–2.12
CYP1B1	Block #1	TAG	32.1	32.5	0.27	1.00	Reference	1.00	Reference
		CGG	23.0	26.1		1.12	0.83–1.51	1.07	0.78–1.46
		CGA	20.3	17.3		0.75	0.44–1.28	0.80	0.57–1.12
		CAG	17.4	18.5		1.06	0.76–1.47	1.08	0.77–1.51
		CAA	7.3	5.6		0.75	0.44–1.28	0.71	0.41–1.23
	Block #2	GTTGGG	30.2	30.8	0.52	1.00	Reference	1.00	Reference
		CTTGAG	20.1	18.6		0.91	0.66–1.24	0.90	0.65–1.24
		CTGGGA	18.1	17.6		0.95	0.69–1.31	0.88	0.63–1.23
		GCTGGG	14.0	14.9		1.05	0.74–1.49	0.97	0.68–1.39
		GTTGGA	7.4	9.8		1.33	0.86–2.07	1.32	0.84–2.08
		CTGGGG	6.2	4.5		0.71	0.40–1.26	0.69	0.39–1.24
CYP17A1	Block #1	GATC	35.0	33.9	0.63	1.00	Reference	1.00	Reference
		AACT	30.4	32.5		1.11	0.86–1.45	1.04	0.80–1.36
		GGTC	19.4	20.6		1.12	0.82–1.53	1.05	0.76–1.45
		AACC	12.1	11.2		0.98	0.68–1.42	0.93	0.63–1.37
	Block #2	ATTT	30.0	30.0	0.92	1.00	Reference	1.00	Reference
		GTGT	23.4	21.1		0.90	0.67–1.22	0.97	0.72–1.32
		GTTT	17.2	16.8		0.98	0.70–1.37	1.00	0.71–1.41
		GTGC	17.0	18.4		1.09	0.79–1.50	1.11	0.80–1.54
		GCGT	10.9	11.9		1.10	0.77–1.59	1.13	0.78–1.65
CYP19A1	Block #1	TAACT	61.3	61.7	0.48	1.00	Reference	1.00	Reference
		TGGTT	16.2	14.7		0.89	0.66–1.22	0.87	0.64–1.20
		AGGCT	6.9	5.5		0.80	0.50–1.28	0.78	0.48–1.27
	Block #2	TCGC	78.7	76.9	0.85	1.00	Reference	1.00	Reference
	Block #2	CCGC	6.9	7.5	0.85	1.16	0.75–1.81	1.13	0.72–1.77
	Block #3	TT	49.3	46.7	0.88	1.00	Reference	1.00	Reference
		CC	37.8	38.6		1.08	0.85–1.37	1.07	0.84–1.37
		CT	12.8	14.4		1.19	0.85–1.68	1.10	0.77–1.56
	Block #4	TCCCTG	53.9	51.5	0.41	1.00	Reference	1.00	Reference
		GCCCCG	15.1	15.2		1.04	0.77–1.42	1.09	0.79–1.49
		GCCCCT	14.3	15.8		1.15	0.84–1.59	1.14	0.83–1.58
		TCCTCT	6.6	4.7		0.73	0.43–1.22	0.70	0.41–1.20
HSD17B1	Block #1	CAT	42.8	41.2	0.37	1.00	Reference	1.00	Reference
		CGC	31.7	30.4		1.00	0.78–1.30	0.93	0.71–1.21
		AGC	20.3	22.1		1.12	0.83–1.51	1.06	0.78–1.44
		CAC	4.6	6.2		1.40	0.86–2.28	1.30	0.79–2.14
SHBG	Block #1	CCG	37.5	39.7	0.46	1.00	Reference	1.00	Reference
		CCC	29.0	27.2		0.88	0.67–1.16	0.82	0.62–1.09
		ACC	24.9	25.4		0.98	0.74–1.29	0.96	0.72–1.27
		CTC	8.6	7.4		0.79	0.51–1.22	0.76	0.49–1.18
	Block #2	CGACC	67.4	70.3	0.14	1.00	Reference	1.00	Reference
		CGCCC	11.0	9.2		0.79	0.55–1.15	0.78	0.53–1.14
		CGCCT	7.8	9.2		1.15	0.78–1.70	1.01	0.68–1.51
		CACCC	7.5	5.1		0.63	0.39–1.01	0.55	0.34–0.90

Haplotypes include SNPs listed in Table I and are presented 5′–3′. Haplotypes with <5% frequency were grouped together and included in the models as one category, but are not presented here.

A global score test was used to evaluate the overall difference in haplotype frequency in cases and controls.

Model-1: estimates are adjusted for the matching variables (age and gender).

Model-2: estimates are adjusted for age, gender, education and smoking (never, former, current and pack-years among smokers).